C
Christoffer Flensburg
Researcher at Walter and Eliza Hall Institute of Medical Research
Publications - 10
Citations - 677
Christoffer Flensburg is an academic researcher from Walter and Eliza Hall Institute of Medical Research. The author has contributed to research in topics: Venetoclax & Germline. The author has an hindex of 5, co-authored 10 publications receiving 351 citations.
Papers
More filters
Journal ArticleDOI
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
Courtney D. DiNardo,Ing Soo Tiong,Ing Soo Tiong,A. Quaglieri,Sarah MacRaild,Sanam Loghavi,Fiona C. Brown,Rachel Thijssen,Giovanna Pomilio,Adam Ivey,Jessica M. Salmon,Christina Glytsou,Shaun Fleming,Shaun Fleming,Qi Zhang,Huaxian Ma,Keyur P. Patel,Steve Kornblau,Zhen Xu,Chong Chyn Chua,Chong Chyn Chua,Xufeng Chen,Piers Blombery,Piers Blombery,Piers Blombery,Christoffer Flensburg,Nik Cummings,Ioannis Aifantis,Hagop M. Kantarjian,David C.S. Huang,Andrew W. Roberts,Andrew W. Roberts,Ian J. Majewski,Marina Konopleva,Andrew H. Wei,Andrew H. Wei +35 more
TL;DR: Molecular determinants of outcome with clinical relevance to patients with AML receiving venetoclax-based combination therapies are identified, highlighting the dynamic and rapid occurrence of therapeutic selection in AML.
Journal ArticleDOI
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Piers Blombery,Piers Blombery,Mary Ann Anderson,Mary Ann Anderson,Mary Ann Anderson,Jia-Nan Gong,Jia-Nan Gong,Rachel Thijssen,Rachel Thijssen,Richard W Birkinshaw,Richard W Birkinshaw,Ella R. Thompson,Ella R. Thompson,Charis E Teh,Charis E Teh,Tamia Nguyen,Tamia Nguyen,Zhen Xu,Christoffer Flensburg,Thomas E Lew,Ian J. Majewski,Daniel H.D. Gray,Daniel H.D. Gray,David Westerman,David Westerman,Constantine S. Tam,Constantine S. Tam,John F. Seymour,John F. Seymour,Peter E. Czabotar,Peter E. Czabotar,David C.S. Huang,David C.S. Huang,Andrew W. Roberts +33 more
TL;DR: The first description of an acquired point mutation in BCL2 arising recurrently and exclusively in venetoclax-treated patients is provided, providing new insights into the pathobiology of venetclax resistance and provides a potential biomarker of impending clinical relapse.
Journal ArticleDOI
SuperFreq: Integrated mutation detection and clonal tracking in cancer
Christoffer Flensburg,Tobias Sargeant,Alicia Oshlack,Alicia Oshlack,Ian J. Majewski,Ian J. Majewski +5 more
TL;DR: SuperFreq is a cancer exome sequencing analysis pipeline that integrates identification of somatic single nucleotide variants (SNVs) and copy number alterations (CNAs) and clonal tracking for both and can be applied in many different experimental settings for the analysis of exomes and other capture libraries.
Posted ContentDOI
SuperFreq: Integrated mutation detection and clonal tracking in cancer
TL;DR: SuperFreq is a cancer exome sequencing analysis pipeline that integrates identification of somatic single nucleotide variants (SNVs) and copy number alterations (CNAs) and clonal tracking for both and can be applied in many different experimental settings for the analysis of exomes and other capture libraries.
Journal ArticleDOI
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Piers Blombery,Piers Blombery,Piers Blombery,Mary Ann Anderson,Mary Ann Anderson,Mary Ann Anderson,Jia-Nan Gong,Jia-Nan Gong,Rachel Thijssen,Rachel Thijssen,Richard W Birkinshaw,Richard W Birkinshaw,Ella R. Thompson,Ella R. Thompson,Charis E Teh,Charis E Teh,Tamia Nguyen,Zhen Xu,Christoffer Flensburg,Thomas E Lew,Ian J. Majewski,Daniel H.D. Gray,David Westerman,David Westerman,David Westerman,Constantine S. Tam,Constantine S. Tam,Constantine S. Tam,John F. Seymour,John F. Seymour,John F. Seymour,Peter E. Czabotar,Peter E. Czabotar,David C.S. Huang,David C.S. Huang,Andrew W. Roberts +35 more
TL;DR: The Gly101Val mutation conferred a selective advantage during continuous exposure to sublethal concentrations of venetoclax in 3-week cultures, and was observed to have elevated BCL-xL by mass cytometry (CyTOF) and when cultured in a bone marrow stromal model.